Apheresis Market Snapshot
“The Apheresis Market is expected to grow at 8.10 % CAGR from 2023 to 2030. It is expected to reach above USD 4.83 billion by 2030 from USD 2.2 billion in 2022.”
Apheresis is a surgical procedure that involves removing blood components like platelets, white blood cells, or plasma from a donor's bloodstream and then reintroducing the remaining blood into the donor at any point during the treatment.
Apheresis involves transferring whole blood from a patient or donor into a centrifuge-like device, where components are separated. Once one segment is removed, the remaining components are re-transfused back into the donor.
The apheresis industry is gaining momentum due to the rise in chronic diseases, injury cases, and biopharmaceutical company demand for plasma.
Concerns about blood safety, sophisticated surgical procedures, and favorable reimbursement are driving this growth. However, high costs of apheresis machines are expected.
installation of apheresis devices through the rental model, as well as fewer blood donations using apheresis due to lack of awareness and the strict donor recruitment criteria, will somewhat restrain market growth in the upcoming years.
The apheresis sector is expanding due to global demand for blood components, government blood donation schemes, and newly approved treatment indications for autoimmune hemolytic anaemia, acute disseminated encephalomyelitis, and cardiac neonatal lupus.
NexSys PCS with persona technology, which tailors plasma collection based on a donor's unique body composition, was approved by the FDA (Food and Drug Administration) in October 2020. It is manufactured by Haemoneticsis, a blood management product firm.
Despite the advent of new revenue streams for the apheresis sector, there are many obstacles in the way that could unintentionally limit growth prospects. The shortage of qualified specialists is a significant impediment to growth.
A technology transformation of epochal proportions has just taken place, revolutionizing the healthcare sector and, consequently, its operations. The expense of acquiring knowledgeable resources rises as a result of the lack of knowledgeable operators, adding to the already high cost of apheresis processes.
Additionally, it is anticipated that the use of therapeutic apheresis in pediatric therapy would contribute to market expansion. It's a difficult technological effort to give children therapeutic apheresis. The majority of apheresis therapies were created through research and clinical trials on adult patients.
However, since diseases like leukaemia and autoimmune disorders are becoming more common in children, more work will need to be put into creating new apheresis therapy strategies that are especially suited for kids.
Additionally, the use of therapeutic apheresis in pediatric care is anticipated to support market expansion. Children's therapeutic apheresis is a technologically difficult task. Studies and clinical trials on adult patients form the foundation for the majority of apheresis therapy.
However, greater efforts should be made to create new apheresis therapy approaches specifically created for children as the prevalence of diseases including leukaemia and autoimmune disorders among children is rising.
>>>Download Sample Report Now:https://marketreportservice.com/request-sample/apheresis-market-54576
Growth Drivers
“The increasing prevalence of diseases is boosting market growth.”
The global apheresis equipment market is expected to expand due to rising illness prevalence, demand for blood components, technological advancements, and increased reimbursement policies. The rising frequency of chronic and acute disorders, demand for blood transfusions, and product introductions will drive the market over the forecast period.
The apheresis market is expected to grow due to the increasing prevalence of blood-related illnesses and technological advancements in equipment, which have reduced treatment duration and simplified procedures, thereby driving market growth.
“The Apheresis market is experiencing steady growth in developed regions due to favorable reimbursement scenarios.”
New therapies like stem cell, immunoglobulin, and radiation are promoting the acceptance of apheresis procedures, boosting the global apheresis market. North American and European governments are promoting high-quality healthcare through programs like Medicare, Medicaid, employee insurance, and the Veterans Health Administration, addressing concerns about the high cost of apheresis procedures.
Restraining Factors
The high cost of therapeutic apheresis procedures, devices, and device installation is expected to hinder the sector's expansion.
The global market growth is expected to be hindered by a lack of awareness, shortage of skilled professionals, and issues related to apheresis procedures.
Apheresis, a condition causing the growth of germ cell tumors, Guillain-Barré syndrome, Paraproteinemia, Waldenstrom's macroglobulinemia, non-Hodgkin's lymphoma, and symptomatic myeloma, is causing various disorders and diseases that hinder market growth.
Opportunity
The apheresis industry is expected to grow due to advancements in medical technology, increased public engagement in blood donation drives, and increased opportunities.
The therapeutics apheresis market is expected to advance due to the increasing demand for plasma-derived medications, established healthcare infrastructure, and global blood component demand.
Apheresis Market Segment Analysis
The apheresis market is segmented based on product, method, procedure, component and end user.
Depending on the product, the disposable & reagent category accounted for the largest market share in 2022. This trend is anticipated to hold true throughout the projection period as a result of the significant developments being made in the creation of blood bags, tubing, and disposable kits. The same category, though, is anticipated to experience significant expansion throughout the course of the apheresis market estimate.
Due to the widespread use of centrifugation in the preparation of blood components like packed red blood cells (PRBCs) and fresh frozen plasma (FFP) in a single-step heavy spin, the centrifugation segment dominated the market size for apheresis as a method in 2022, and this trend is anticipated to continue during the forecast period.
A substantial portion of the worldwide apheresis market is held by blood centers, which support the expansion of the donor apheresis sector. As a result, the donor/automated segment led the apheresis market share by procedure in 2022, and this trend is anticipated to continue over the forecast period. Additionally, the industry has grown as a result of an increase in apheresis platelet and plasma contributions.
Due to its widespread application in the treatment of hematologic and neurological illnesses as well as renal and metabolic diseases, the plasma (plasmapheresis) segment dominated the market by component in 2022, and this trend is anticipated to persist over the forecast period. The platelet segment, however, is anticipated to experience significant increase over the course of the projection period due to the rising popularity of platelet apheresis operations worldwide.
Given that donor apheresis is a key component of the apheresis industry and that blood centers perform the majority of donor apheresis procedures globally, the blood centers segment dominated the market by end user in 2022, and this trend is anticipated to continue during the forecast period.
Apheresis Market Player
The apheresis market key players includes
- Kawasumi Laboratories
- Asahi Kasei Medical
- Kaneka Corporation
- Cerus Corporation
- Terumo BCT
- Braun Melsungen AG
- Haemonetics Corporation
- Nikkiso
- HemaCareKawasumi Laboratories
- Asahi Kasei Medical
- Kaneka Corporation
- Cerus Corporation
- Terumo BCT
- Braun Melsungen AG
- Haemonetics Corporation
- Nikkiso
- HemaCare Corporation
- Fresenius Kabi. Corporation
New Developments
30-Jun-2023 Maude Adverse Event Report: Kaneka Corporation Liposorber La-15 System; Ldl Apheresis System
The ldl-apheresis (ldl-a) with liposorber la-15 system was applied to a (b)(6) years of age female patient (hd), with diabetes mellitus (dm) and dementia, for the treatment of her arterio sclerosis obliterans (aso).In the first ldl-a of the pt, she developed a severe hypotension with a shock symptom at around 10-15 minutes after starting the procedure (at 11:07 am), and the procedure was immediately terminated.
19 April 2022: Asahi Kasei Medical had completed its acquisition of Bionova Scientific, LLC, a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies as announced on April 19, 2022. The acquisition closed on May 31, 2022 (US Pacific time).
21 December 2021: ExThera Medical and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for ExThera's Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100). Per the agreement structure, ExThera Medical and Asahi Kasei Medical will collaborate to obtain regulatory approval of Seraph 100 for commercialization in Japan.
Apheresis Market Regional Analysis
With a revenue share of 35.2% in the global market in 2022, North America topped the field and is predicted to keep doing so throughout the forecast period. The key drivers propelling the market in North America are the rising prevalence of blood-related ailments such kidney disease, metabolic disease, cancer, and neurological disorders, the rising number of donors, and the demand for blood components. Nearly 6.8 million Americans donate blood annually, according to The American National Red Cross. Furthermore, someone requires blood or platelets every two seconds. As a result, the market in the United States is being driven by an increase in both the number of donation camps and blood transfusions.
On the other hand, the Asia Pacific market is anticipated to see the greatest CAGR. One of the major factors contributing to this increase in revenue share is the rising prevalence of blood illnesses necessitating plasma and platelet transfusions in developing nations like China and India. Additionally, during the projection period, the industry is anticipated to benefit from an improved growth environment due to the region's expanding healthcare practitioner population and improved healthcare infrastructure.
Segments Covered in the Apheresis Market Report
Apheresis Market by Product
- Devices
- Disposable & Reagents
- Software
Apheresis Market by Method
- Centrifugation
- Membrane Separation
- Selective Absorption
Apheresis Market by Procedure
- Donor/Automated Apheresis
- Therapeutic Apheresis
Apheresis Market by Component
- Plasma
- Platelets
- Leukocytes
- Lymphocytes
- RBCs
Apheresis Market by End User
- Blood Centers
- Hospitals
- Others
The above information has been provided for the following regions and countries:
North America
Europe
- UK
- Germany
- France
- Italy
- Russia
Asia Pacific
- China
- India
- Japan
- South Korea
Latin America
MEA
- UAE
- Saudi Arabia
- South Africa
Frequently Asked Questions
What is the worth of apheresis market?
The Apheresis Market is expected to grow at 8.10 % CAGR from 2023 to 2030. It is expected to reach above USD 4.83 billion by 2030 from USD 2.2 billion in 2022.
What is the size of the North America apheresis industry?
North America held more than 35% of the apheresis market revenue share in 2022 and will witness expansion in the forecast period.
What are some of the market's driving forces?
The market for apheresis is primarily driven by the rising prevalence of chronic diseases, the rise in the number of injury cases, the rising demand from biopharmaceutical companies for source plasma, the rising demand for blood components and the rise in concerns about the safety of blood, the rise in the number of complex surgical procedures, and the favourable reimbursement for apheresis procedures.
Which are the top companies to hold the market share in apheresis market?
The apheresis market key players includes Kawasumi Laboratories, Asahi Kasei Medical, Kaneka Corporation, Cerus Corporation, Terumo BCT, B. Braun Melsungen AG, Haemonetics Corporation, Nikkiso, HemaCare Corporation, Fresenius Kabi.
What is the leading application of apheresis market?
Due to its widespread application in the treatment of hematologic and neurological illnesses as well as renal and metabolic diseases, the plasma (plasmapheresis) segment dominated the market by component in 2022, and this trend is anticipated to persist over the forecast period.
1.SUMMARY
1.1. Apheresis Market Overview
1.2. Key Insights
1.3. Report Scope
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
- DECISION-MAKING SUMMARY
- INTRODUCTION
3.1. Overview of Apheresis
3.2. Key Historical Events
3.3. Structure
3.4. Biochemical Interaction
3.5. Target Indications
3.6. Advantages of Apheresis
3.7 Challenges associated with Apheresis
3.8. Future Perspectives.
- MARKET LANDSCAPE
4.1. Methodology
4.2 Apheresis: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.2.6. Most Active Players
- COMPANY
5.1. Company Overview
5.1.2 Management Team
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
- PARTNERSHIPS AND COLLABORATIONS
6.1. Partnership Models
6.2. Apheresis: Partnerships and Collaborations
6.2.1. Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Analysis by Type of Partner
6.2.5. Analysis by Year of Partnership and Type of Partner
6.2.6. Analysis by Type of Partnership and Type of Partner
6.2.7. Analysis by Type of Partner and Parent Company Size
- ACADEMIC GRANTS ANALYSIS
7.1. Methodology and Key Parameters
7.2. Apheresis: Academic Grants Analysis
7.2.1. Analysis by Year of Grant Award
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Funding Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Funding Institute Center and Support Period
7.2.6. Analysis by Type of Grant Application
7.2.7. Analysis by Purpose of Grant
- PUBLICATION ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Apheresis: Publication Analysis
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Publication
8.2.3. Analysis by Type of Conjugate
8.2.4. Analysis by Target Indication
8.2.5. Analysis by Copyright Holder
8.2.6. Word Cloud: Emerging Focus Area
8.2.7. Most Active Publishers: Analysis by Number of Publications
- SUCCESS PROTOCOL ANALYSIS
9.1. Methodology and Key Parameters
9.2. Key Assumptions and Scoring Criteria
9.3. Success Protocol Analysis
9.4. Assessment of Approved Apheresis
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies
- Kawasumi Laboratories
- Asahi Kasei Medical
- Kaneka Corporation
- Cerus Corporation
- Terumo BCT
- Braun Melsungen AG
- Haemonetics Corporation
- Nikkiso
- HemaCareKawasumi Laboratories
- Asahi Kasei Medical
- Kaneka Corporation
- Cerus Corporation
- Terumo BCT
- Braun Melsungen AG
- Haemonetics Corporation
- Nikkiso
- HemaCare Corporation
- Fresenius Kabi. Corporation
